Lopez-Rios de Castro, R. | Search bioRxiv

bioRxiv2026

Kinase inhibitors can change protonation or tautomeric state upon binding

The binding affinity of a ligand to a protein is influenced by the protonation and tautomeric states of both partners. However, this relationship remains under-investigated due to the limited availability of computational tools capable of considering all charge and tautomer states in a scalable manner to study clinically relevant systems. Here, we use Multi-Conformation Continuum Electrostatics (MCCE) to calculate the protonation and tautomer distributions of nine kinase domains bound to 18 FDA-approved inhibitors while considering their Boltzmann-ensemble. Our simulations show that protein net charge and proton distribution remain largely stable even upon binding charged inhibitors. Our results find that individual inhibitor charges are dynamic, frequently increasing, or decreasing upon binding a specific protein target. Kinase-inhibitor binding significantly shifts the relative probabilities of low-energy states ({Delta}G < 2.5 kcal/mol), though it does not recruit higher-energy conformers into the bound population. Our consideration of all possible charge states and tautomers enable us to identify when tautomer have significant significant free binding energy differentials (3-6kcal/mol). In turn, we find that minority species can become the dominant component in the bound state, emphasizing the necessity of considering ensemble-wide protonation and tautomer states to accurately predict protein-ligand binding energetics.

biophysics↗

bioRxiv2024

Lessons learned during the journey of data: from experiment to model for predicting kinase affinity, selectivity, polypharmacology, and resistance

Recent advances in machine learning (ML) are reshaping drug discovery. Structure-based ML methods use physically-inspired models to predict binding affinities from protein:ligand complexes. These methods promise to enable the integration of data for many related targets, which addresses issues related to data scarcity for single targets and could enable generalizable predictions for a broad range of targets, including mutants. In this work, we report our experiences in building KinoML, a novel framework for ML in target-based small molecule drug discovery with an emphasis on structure-enabled methods. KinoML focuses currently on kinases as the relative structural conservation of this protein superfamily, particularly in the kinase domain, means it is possible to leverage data from the entire superfamily to make structure-informed predictions about binding affinities, selectivities, and drug resistance. Some key lessons learned in building KinoML include: the importance of reproducible data collection and deposition, the harmonization of molecular data and featurization, and the choice of the right data format to ensure reusability and reproducibility of ML models. As a result, KinoML allows users to easily achieve three tasks: accessing and curating molecular data; featurizing this data with representations suitable for ML applications; and running reproducible ML experiments that require access to ligand, protein, and assay information to predict ligand affinity. Despite KinoML focusing on kinases, this framework can be applied to other proteins. The lessons reported here can help guide the development of platforms for structure-enabled ML in other areas of drug discovery.

biophysics↗